- Trials with a EudraCT protocol (10,988)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
10,988 result(s) found.
Displaying page 242 of 550.
EudraCT Number: 2011-004214-42 | Sponsor Protocol Number: RETIRD02 | Start Date*: 2012-09-03 | ||||||||||||||||
Sponsor Name:QLT Inc. | ||||||||||||||||||
Full Title: An Open-Label Study to Evaluate the Effects of Repeated Treatments of Oral QLT091001 on Safety and Vision Outcome in Subjects with Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due ... | ||||||||||||||||||
Medical condition: Leber Congenital Amaurosis Retinitis pigmentosa | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) DE (Completed) NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005268-25 | Sponsor Protocol Number: CCD-05993AA1-09 | Start Date*: 2014-08-01 | |||||||||||
Sponsor Name:CHIESI FARMACEUTICI SPA | |||||||||||||
Full Title: A MULTINATIONAL, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PLACEBO-CONTROLLED , 2-WAY CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GLYCOPYRROLATE BROMIDE ADMINISTERED VIA PMDI (CHF 5259), FO... | |||||||||||||
Medical condition: CHRONIC OBSTRUCTIVE PULMONARY DISEASE | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000616-28 | Sponsor Protocol Number: OCTO_038 | Start Date*: 2013-08-22 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: Phase II trial of Linsitinib (anti-IGFR/IR) in patients with relapsed and/or refractory Ewing Sarcoma | |||||||||||||
Medical condition: Relapsed and/or refractory Ewing sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004302-26 | Sponsor Protocol Number: 201350 | Start Date*: 2014-09-05 | |||||||||||
Sponsor Name:Santen Oy | |||||||||||||
Full Title: A phase I study to evaluate the pharmacokinetics, safety and tolerability of preservative free tafluprost ophthalmic solution (0.0015%) in pediatric patients diagnosed with glaucoma or ocular hyper... | |||||||||||||
Medical condition: Glaucoma or Ocular Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) HU (Completed) SK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006174-47 | Sponsor Protocol Number: FC-004 | Start Date*: 2012-06-08 | |||||||||||
Sponsor Name:ProFibrix BV | |||||||||||||
Full Title: A Phase 3, Randomized, Single-Blind, Controlled Trial of Topical Fibrocaps™ in Intraoperative Surgical Haemostasis | |||||||||||||
Medical condition: Intraoperative Surgical Hemostasis (Spinal Surgery, Vascular Surgery, Hepatic resection, Soft tissue dissection) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Completed) GB (Completed) | |||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2012-005000-17 | Sponsor Protocol Number: CAFQ056A2225 | Start Date*: 2013-08-08 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, parallel-group proof of concept study to evaluate the effect of AFQ056 in obsessive compulsive disorder (OCD) patients resistant to Selective Seroton... | |||||||||||||
Medical condition: obsessive compulsive disorder (OCD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003704-39 | Sponsor Protocol Number: NEAT22/SSAT060 | Start Date*: 2014-04-01 |
Sponsor Name:St Stephen's AIDS Trust [...] | ||
Full Title: An open label study examining the efficacy and cardiovascular risk of immediate versus deferred switch from a boosted PI to dolutegravir (DTG) in HIV infected patients with stable virological suppr... | ||
Medical condition: HIV infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) BE (Completed) ES (Ongoing) IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-000805-27 | Sponsor Protocol Number: MEIN/10/Ran-Did/001 | Start Date*: 2012-10-23 | |||||||||||
Sponsor Name:Menarini International Operations Luxembourg S.A., Avenue de la Gare, 1611 Luxembourg, Luxembourg | |||||||||||||
Full Title: Effect of Ranolazine in Heart Failure Patients with Preserved Ejection Fraction | |||||||||||||
Medical condition: Heart failure patients with preserved ejection fraction (HFpEF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003347-35 | Sponsor Protocol Number: MK-3682-012 | Start Date*: 2014-10-30 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 with Either MK-8742 or MK-8408 in Subjects with Chronic HCV GT3,... | |||||||||||||
Medical condition: Chronic hepatitis C infected patient | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004066-20 | Sponsor Protocol Number: AC-055-403 | Start Date*: 2015-05-14 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd. | |||||||||||||
Full Title: A prospective, multicenter, single-arm, open-label, phase 4 study to evaluate the effects of macitentan on Right vEntricular remodeling in Pulmonary ArterIal hypeRtension assessed by cardiac magnet... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001572-22 | Sponsor Protocol Number: PDY14192 | Start Date*: 2015-12-01 | |||||||||||
Sponsor Name:SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT | |||||||||||||
Full Title: An exploratory, randomized, double-blind, placebo-controlled study of the effects of dupilumab on airway inflammation of adults with persistent asthma | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) SE (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004084-39 | Sponsor Protocol Number: 1002-048 | Start Date*: 2017-04-19 | ||||||||||||||||
Sponsor Name:Esperion Therapeutics Inc., | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180 mg/day as Add-on to Ezetimibe Therapy in Patie... | ||||||||||||||||||
Medical condition: This study is to assess the efficacy of bempedoic acid 180 mg/day versus placebo in decreasing low-density lipoprotein cholesterol (LDL-C) when added to ezetimibe therapy in patients with high LDL-... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) GB (Completed) DE (Completed) CZ (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-002446-23 | Sponsor Protocol Number: GS-US-342-1143 | Start Date*: 2017-01-19 | ||||||||||||||||
Sponsor Name:Gilead Sciences, Inc. | ||||||||||||||||||
Full Title: A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children with Chronic HCV Infection | ||||||||||||||||||
Medical condition: Chronic Hepatitis C virus infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) BE (Completed) Outside EU/EEA IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-003035-35 | Sponsor Protocol Number: HS-14-499 | Start Date*: 2015-11-09 |
Sponsor Name:Braeburn Pharmaceuticals | ||
Full Title: An Open-Label Multicenter Study Assessing the Long-Term Safety of a Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injection Depot of Buprenorphine (CAM2038) in Adult Outpatients with Opioi... | ||
Medical condition: Opioid Use Disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) SE (Completed) DK (Completed) HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-003089-96 | Sponsor Protocol Number: 204851 | Start Date*: 2016-01-06 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A multi-centre Phase IIa double-blind, placebo-controlled study to investigate the efficacy and safety of GSK3196165 in subjects with inflammatory hand osteoarthritis. | |||||||||||||
Medical condition: Inflammatory Hand Osteoarthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) NL (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003028-22 | Sponsor Protocol Number: RGT100-001 | Start Date*: 2017-01-26 | |||||||||||||||||||||
Sponsor Name:Rigontec GmbH | |||||||||||||||||||||||
Full Title: A Phase I/II, Multicenter, Open-label, Clinical Trial of Intratumoral/Intralesional Administration of RGT100 in Subjects with Advanced or Recurrent Tumors | |||||||||||||||||||||||
Medical condition: Advanced or recurrent tumors | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) GB (Completed) ES (Prematurely Ended) FR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-002620-26 | Sponsor Protocol Number: INCB18424-268 | Start Date*: 2014-12-22 | |||||||||||
Sponsor Name:Incyte Corporation | |||||||||||||
Full Title: A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer | |||||||||||||
Medical condition: Metastatic or advanced HER-2 negative breast cancer patients who have already received treatment with anthracyclines and paclitaxel. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) GB (Prematurely Ended) PT (Prematurely Ended) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003522-16 | Sponsor Protocol Number: RA101495-01.201 | Start Date*: 2017-06-20 | |||||||||||
Sponsor Name:Ra Pharmaceuticals, Inc. | |||||||||||||
Full Title: A PHASE 2 MULTICENTER,OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RA101495 IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLO... | |||||||||||||
Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) GB (Completed) HU (Completed) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-005230-30 | Sponsor Protocol Number: SPX-101-CF-201 | Start Date*: 2017-07-14 | |||||||||||
Sponsor Name:Spyryx Biosciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of SPX-101 Inhalation Solution in Subjects with Cystic Fibrosis (HOPE-1 STUDY: HYDRATION FOR OPTIMA... | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) PT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003821-40 | Sponsor Protocol Number: NN7170-4345 | Start Date*: 2017-02-15 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Evaluation of safety following Immune Tolerance Induction treatment with turoctocog alfa in patients with haemophilia A following inhibitor development in NN7170-4213 trial | |||||||||||||
Medical condition: Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) AT (Completed) BG (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
